Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.